NUREMBERG, Germany, March 10, 2026, 22:44 CET
Intel rolled out its Core Series 2 processors for industrial gear on Monday, while also offering an early look at its Health & Life Sciences Edge AI suite at Embedded World in Nuremberg. The company is sharpening its edge AI focus—bringing processing closer to machines and sensors instead of relying solely on distant cloud servers. Factories, robotics setups, and patient monitoring systems are all in its sights.
The timing is crucial. Intel, under Chief Executive Lip-Bu Tan, is under pressure to prove it can deliver growth beyond the AI data-center sector as the company heads in a new direction. Back in January, management guided to first-quarter revenue between $11.7 billion and $12.7 billion, with adjusted earnings projected just at break-even—both numbers missing Wall Street’s mark. The company also admitted then it couldn’t meet demand for server CPUs that are paired with Nvidia’s top AI chips.
These new chips target applications where consistent, on-time responses matter—deterministic performance, as Intel puts it. Each can pack in as many as 12 P-cores, or performance cores. For healthcare, Intel’s toolkit is designed so device makers can experiment with AI-driven tools like heart rhythm analysis, touch-free vital sign checks, and 3D patient tracking that preserves anonymity.
“The next wave of AI is coming to the edge,” Michael Masci, Intel’s vice president of product management, said this day during a press briefing. Intel’s pitch, according to Stephen Sopko, analyst-in-residence at HyperFrame Research, is “a two-chip story.” He explained to Data Center Knowledge: the company is putting its Core Series 2 chips on control-oriented tasks, while Core Ultra Series 3 handles AI inference—where the model produces its results. All About Circuits
Intel is squaring off with AMD in embedded processors and taking aim at Nvidia’s edge AI hardware. According to Tom’s Hardware, Intel stacked its new chips against AMD’s Ryzen 7 9700X, while also spotlighting the Core Ultra Series 3 in robotics, positioning it as a direct challenger to Nvidia’s Jetson AGX Orin.
Intel stock picked up 2.6%, trading at $46.78 as of 21:28 UTC on Tuesday. The session started at $45.42, according to market data. Shares had surged 84% in 2025, as investors threw support behind Tan’s restructuring moves and a streak of external investments, Reuters noted in January.
Tan continues to reshape the business. On March 4, Reuters said Intel was taking another look at its earlier decision to reserve the 18A manufacturing process mostly for itself, now weighing whether to open it up to external clients. A day before, the company announced board chair Frank Yeary will step down in May, with longtime chip veteran Craig Barratt set to take over.
But a flashy product launch doesn’t answer the tougher questions. Michael Schulman, chief investment officer at Running Point Capital, told Reuters back in January that Intel’s turnaround was still “supply-constrained rather than demand-constrained.” That followed word from the company itself that it was walking away from some server-chip sales. Separately, UBS has flagged rising memory prices as a possible drag on PC demand this year. Reuters
Intel faces fresh political headwinds. Just last week, a bipartisan group of U.S. lawmakers, including Elizabeth Warren and Tom Cotton, flagged national-security worries tied to Intel’s testing of ACM Research tools—their China connections already under a sanctions cloud. Intel maintains that ACM’s tools aren’t part of its production lines and says it follows U.S. law.
Intel says Core Series 2 and Core Ultra Series 3 systems are already out, with the Health & Life Sciences suite expected to see wider rollout in the second quarter. The launch is part of a bigger push through 2026, as the company tries to claw back share from AMD on the PC side and from Taiwan Semiconductor Manufacturing Co when it comes to manufacturing.
